ERBB2 and glioblastoma: In a preclinical study, trivalent CAR-T cells (targeting IL13Rα2, EphA2, and HER2) were tested in order to overcome the antigen pair diversity seen in GBM patients and thus the insufficient antigen coverage of dual CAR-T cells.